Courts across the country, and particularly in California, have long been reluctant to construe standard commercial general liability insurance policies to provide coverage for patent infringement lawsuits. However, the Ninth Circuit's recent decision in <i>Hyundai Motor v. Nat. Union Fire Ins.</i>, suggests that, at least when the patented invention is itself a method of advertising, an insurer will owe a duty to defend a patent infringement lawsuit under the "advertising injury" provisions of many standard CGL policies.

The purpose of this article is to share with you what our Client Feedback interviews have revealed about attaining the status of TA in a much more concise manner than the various books that have been written on the subject.

With the enactment of the Patient Protection and Affordable Care Act on March 23, 2010, President Obama and the Congress have ushered in what will be, barring major amendment or repeal, a new era for the regulation of private health insurance coverage in the U.S.

Features

Staying competitive means always being on the lookout for new ways to accomplish tasks faster, cheaper and better. The stellar tools highlighted herein will help you be more effective on the job ' and, perhaps, more secure.

Highlights of the latest intellectual property news from around the country.

Since Jan. 1, 2010, over 130 cases have been filed that accuse defendants of false patent marking. This recent tidal wave of false marking litigation contrasts with the relative calm of the past in which only approximately 40 false patent marking cases total were filed from 2000'2009. What caused the underwater earthquake? The decision of the Court of Appeals for the Federal Circuit in <i>Forest Group, Inc. v. Bon Tool Co.</i>

Features

It's time that legal marketing executives take a risk and launch a creative media campaign that reshapes the industry's image and increases the unaided brand recognition of their firm over the virtual stealth existence of their competitors.

Features

In Association for Molecular Pathology v. USPTO, the United States District Court for the Southern District of New York invalidated patents related to isolated BRCA1 and BRCA2 breast and ovarian cancer susceptibility genes. The surprising aspect of the decision was the reason for invalidity ' the district court held that the isolated genes did not constitute patentable subject matter under 35 U.S.C. ' 101.